文献速递儿科与产科急症重症综合管理与镇静镇痛

右美托咪定对产前抑郁产妇产后抑郁的影响:一项随机临床试验

Effect of Dexmedetomidine on Postpartum Depression in Women With Prenatal Depression: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-01-02
一句话结论产前抑郁剖宫产产妇产后早期静脉输注右美托咪定0.5 μg/kg并复合舒芬太尼镇痛,可显著降低产后7天和42天产后抑郁筛查阳性率。

这项随机临床试验纳入中国湖南2家医院338例产前抑郁筛查阳性(爱丁堡产后抑郁量表评分>9)且择期剖宫产的产妇。右美托咪定组产后静脉输注右美托咪定0.5 μg/kg(10分钟),随后经患者自控静脉镇痛给予右美托咪定复合舒芬太尼48小时;对照组给予0.9%氯化钠及舒芬太尼镇痛。产后7天筛查阳性率右美托咪定组12.6% vs 对照组32.1%(RR 0.39,95%CI 0.25-0.62,P<.001),产后42天11.4% vs 30.3%(RR 0.38,95%CI 0.23-0.61,P<.001)。不良事件总发生率无显著差异(27.2% vs 19.5%,P=.10),但低血压发生率升高(18.3% vs 9.5%,RR 2.15,95%CI 1.13-4.10,P=.02)。

要点

  • 产前爱丁堡产后抑郁量表评分>9的剖宫产产妇,产后静脉输注右美托咪定0.5 μg/kg(10分钟)并复合舒芬太尼镇痛48小时,产后7天筛查阳性率12.6% vs 对照组32.1%(RR 0.39,95%CI 0.25-0.62,P<.001)。
  • 产后42天筛查阳性率右美托咪定组11.4% vs 对照组30.3%(RR 0.38,95%CI 0.23-0.61,P<.001),效果维持至产后6周。
  • 不良事件总发生率右美托咪定组27.2% vs 对照组19.5%,无显著差异(P=.10)。
  • 低血压发生率右美托咪定组18.3% vs 对照组9.5%,风险比为2.15(95%CI 1.13-4.10,P=.02),用药期间需监测血压。
  • 研究在中国湖南2家医院进行,纳入18岁及以上、择期剖宫产、产前抑郁筛查阳性的产妇。

适用人群与场景

  • 中国湖南2家医院、2022年3月28日至2023年4月16日招募的18岁及以上、产前抑郁筛查阳性(爱丁堡产后抑郁量表评分>9)、拟行择期剖宫产的产妇,共338例。

诊断标准与关键阈值

  • 产前抑郁筛查阳性定义:爱丁堡产后抑郁量表评分>9。
  • 产后抑郁筛查阳性定义:产后爱丁堡产后抑郁量表评分>9。

处置流程与药物剂量

  • 右美托咪定组:胎儿娩出后静脉输注右美托咪定0.5 μg/kg,输注时间10分钟;随后经患者自控静脉镇痛给予右美托咪定复合舒芬太尼,持续48小时。
  • 对照组:胎儿娩出后静脉输注0.9%氯化钠,输注时间10分钟;随后经患者自控静脉镇痛给予舒芬太尼,持续48小时。

红旗征与不能漏的情况

  • 右美托咪定组低血压发生率18.3%(31/169) vs 对照组9.5%(16/169),风险比2.15(95%CI 1.13-4.10,P=.02)。

研究设计与关键结果

  • 研究类型:随机临床试验,纳入338例产前抑郁筛查阳性剖宫产产妇,1:1随机分为右美托咪定组和对照组,按意向性分析。
  • 主要终点产后7天筛查阳性率:右美托咪定组12.6%(21/167) vs 对照组32.1%(53/165),风险比0.39(95%CI 0.25-0.62),P<.001。
  • 主要终点产后42天筛查阳性率:右美托咪定组11.4%(19/167) vs 对照组30.3%(50/165),风险比0.38(95%CI 0.23-0.61),P<.001。
  • 不良事件总发生率:右美托咪定组27.2%(46/169) vs 对照组19.5%(33/169),无显著差异(P=.10)。
  • 低血压发生率:右美托咪定组18.3%(31/169) vs 对照组9.5%(16/169),风险比2.15(95%CI 1.13-4.10),P=.02。
  • 参与者均为女性,平均(SD)年龄31.5(4.1)岁。

证据类型、等级与局限

  • 证据类型:随机临床试验。

对床旁实践的改变

  • 对产前爱丁堡产后抑郁量表评分>9、择期剖宫产的产妇,产后早期静脉输注右美托咪定0.5 μg/kg(10分钟)并复合舒芬太尼患者自控静脉镇痛48小时,可降低产后7天和42天产后抑郁筛查阳性率(作者结论)。
  • 用药期间应监测血压,因右美托咪定组低血压发生率高于对照组(18.3% vs 9.5%,RR 2.15,95%CI 1.13-4.10,P=.02)。

指南或共识出处

  • 中国临床试验注册中心注册号:ChiCTR2200057213。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Postpartum depression (PPD) is emerging as a major public health problem worldwide. Although the particular period and context in which PPD occurs provides an opportunity for preventive interventions, there is still a lack of pharmacologic prevention strategies for PPD.

OBJECTIVE: To assess the efficacy and safety of dexmedetomidine for prevention of PPD among women with prenatal depression undergoing cesarean delivery.

DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial enrolled 338 women who screened positive for prenatal depression at 2 hospitals in Hunan, China from March 28, 2022, to April 16, 2023. Women with an Edinburgh Postnatal Depression Scale score of more than 9 who were 18 years of age or older and were scheduled for elective cesarean delivery were eligible.

INTERVENTIONS: Eligible participants were randomly assigned in a 1:1 ratio to either the dexmedetomidine group or the control group via centrally computer-generated group randomization. Dexmedetomidine, 0.5 μg/kg and 0.9% saline were intravenously infused for 10 minutes after delivery in the dexmedetomidine and control groups, respectively. After infusion, sufentanil or dexmedetomidine plus sufentanil was administered via patient-controlled intravenous analgesia for 48 hours in the control group and dexmedetomidine group, respectively.

MAIN OUTCOMES AND MEASURES: The primary outcome was positive PPD screening results at 7 and 42 days post partum, defined as a postpartum Edinburgh Postnatal Depression Scale score of more than 9. Analysis was on an intention-to-treat basis.

RESULTS: All 338 participants were female, with a mean (SD) age of 31.5 (4.1) years. Positive PPD screening incidence at 7 and 42 days post partum in the dexmedetomidine group vs the control group was significantly decreased (day 7, 21 of 167 [12.6%] vs 53 of 165 [32.1%]; risk ratio, 0.39 [95% CI, 0.25-0.62]; P < .001; day 42, 19 of 167 [11.4%] vs 50 of 165 [30.3%]; risk ratio, 0.38 [95% CI, 0.23-0.61]; P < .001). The dexmedetomidine group showed no significant difference in adverse events vs the control group (46 of 169 [27.2%] vs 33 of 169 [19.5%]; P = .10), but the incidence of hypotension increased (31 of 169 [18.3%] vs 16 of 169 [9.5%]; risk ratio, 2.15 [95% CI, 1.13-4.10]; P = .02).

CONCLUSIONS AND RELEVANCE: Dexmedetomidine administration in the early postpartum period significantly reduced the incidence of a positive PPD screening and maintained a favorable safety profile.

TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR2200057213.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Zhou Y, Bai Z, Zhang W, et al. Effect of Dexmedetomidine on Postpartum Depression in Women With Prenatal Depression: A Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38270949. doi:10.1001/jamanetworkopen.2023.53252

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。